Nascent Biotech, Inc. Share Price Other OTC
Equities
NBIO
US63108Q1013
Biotechnology & Medical Research
Sales 2022 | 1 78.74 | Sales 2023 | - | Capitalization | 7.16M 564M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -2M -157M | EV / Sales 2022 | 6,213,671 x |
Net cash position 2022 | 94.41K 7.43M | Net Debt 2023 | 217K 17.12M | EV / Sales 2023 | - |
P/E ratio 2022 |
-13.1
x | P/E ratio 2023 |
-2.38
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Carrick
CEO | Chief Executive Officer | 56 | 14/07/14 |
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14/07/14 |
Douglas Karas
BRD | Director/Board Member | 59 | 03/04/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14/07/14 |
Sean Carrick
CEO | Chief Executive Officer | 56 | 14/07/14 |
Douglas Karas
BRD | Director/Board Member | 59 | 03/04/16 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |